Can Statins Cause Low Hemoglobin?
Statins are not recognized as a cause of anemia or low hemoglobin in established guidelines or FDA labeling, and the evidence linking statins to anemia is conflicting and of low quality.
Evidence from Guidelines and FDA Labeling
The most authoritative sources—the 2002 ACC/AHA/NHLBI clinical advisory on statin safety 1 and the 2013 Canadian Working Group consensus update 2—do not list anemia or low hemoglobin as recognized adverse effects of statin therapy. These guidelines comprehensively detail known statin adverse effects including myopathy, rhabdomyolysis, hepatic dysfunction, and new-onset diabetes, but make no mention of hematologic effects.
The FDA labeling for rosuvastatin 3 similarly does not include anemia, low hemoglobin, or any hematologic adverse effects in its warnings, precautions, or adverse reactions sections. The label focuses on myopathy/rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, and increases in HbA1c/glucose.
Conflicting Research Evidence
The research literature presents contradictory findings:
Evidence suggesting harm:
- A 2023 South Korean population-based cohort study found statin use increased the risk of iron deficiency anemia up to 5.04-fold (95% CI: 2.11-12.03) 4
- A 2020 Japanese case series reported atorvastatin-induced anemia with elevated LDH that resolved upon drug discontinuation 5
Evidence suggesting benefit:
- A 2018 randomized crossover trial in CKD patients showed atorvastatin increased hemoglobin slightly (from 11.6 to 11.9 g/dL, p=0.002) by decreasing hepcidin levels 6
- A 2022 meta-analysis found statin use increased hemoglobin by 0.84 g/dL in CKD/ESKD patients 7
Clinical Interpretation for Your Patient
For a 48-year-old man with borderline hemoglobin (130 g/L) on statin therapy presenting with fatigue, weakness, and dyspnea:
Do not attribute the anemia to the statin as a first-line explanation. The lack of recognition in authoritative guidelines and FDA labeling means this is not an established adverse effect.
Pursue standard anemia workup:
- Complete blood count with indices (MCV, MCH, MCHC)
- Reticulocyte count
- Iron studies (serum iron, TIBC, ferritin)
- Vitamin B12 and folate
- Renal function (creatinine, eGFR)
- Thyroid function
- Occult blood loss evaluation if indicated
Consider statin as a potential contributor only after excluding common causes (iron deficiency, B12/folate deficiency, chronic disease, renal insufficiency, GI blood loss, hypothyroidism, malignancy).
If no other cause is identified and temporal relationship is strong: Consider a trial off the statin for 4-8 weeks with hemoglobin monitoring. If hemoglobin improves, this suggests causality; if unchanged, the statin is unlikely responsible.
Important Caveats
- The South Korean study 4 showing increased anemia risk is observational and subject to confounding
- The beneficial effects seen in CKD patients 6, 7 may not generalize to patients with normal renal function
- Hemoglobin of 130 g/L in a 48-year-old man is at the lower limit of normal but may not represent true pathology
- Fatigue and weakness have multiple etiologies; do not anchor on the statin without comprehensive evaluation
The absence of anemia from authoritative statin safety profiles strongly suggests that if statins do affect hemoglobin, the effect is rare, clinically insignificant, or confounded by other factors.